Active immunization against hepatitis A in dialysis patients

Background. This study investigated the feasibility, immunogenicity, and reactogenicity of hepatitis A vaccination in end‐stage renal failure patients who were on chronic intermittent haemodialysis. Methods. Forty‐three subjects were vaccinated with an inactivated hepatitis A vaccine according to a...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 2002-10, Vol.17 (10), p.1825-1828
Main Authors: Fleischmann, Erwin Hermann, Kruppenbacher, Johannes, Bock, Hans Ludwig, Weber, Manfred
Format: Article
Language:English
Subjects:
Adult
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
dialysis patients
Emergency and intensive care: renal failure. Dialysis management
feasibility
Feasibility Studies
Female
hepatitis A
Hepatitis A - immunology
Hepatitis A - prevention & control
Hepatitis A Antibodies - analysis
Hepatitis A Vaccines - administration & dosage
Humans
immunization
immunogenicity
Injections, Intramuscular
Injections, Subcutaneous
Intensive care medicine
Kidney Failure, Chronic - therapy
Male
Medical sciences
Middle Aged
reactogenicity
Renal Dialysis
Vaccination - adverse effects
Vaccines, Inactivated - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. This study investigated the feasibility, immunogenicity, and reactogenicity of hepatitis A vaccination in end‐stage renal failure patients who were on chronic intermittent haemodialysis. Methods. Forty‐three subjects were vaccinated with an inactivated hepatitis A vaccine according to a 0‐, 1‐, and 6‐month immunization schedule. Two groups were established who received the vaccine either intramuscularly (group A, n=30) or subcutaneously (group B, n=13). Results. All patients in group A and 12/13 in group B developed antibodies against hepatitis A. The geometric mean titres (GMT) were high and similar to those observed in healthy subjects. There was a tendency to higher GMT in the group who received the vaccine subcutaneously. No clinically significant adverse events were observed, and the liver enzyme profile showed no abnormalities. Conclusions. We showed that hepatitis A vaccination of dialysis patients is feasible, well tolerated and immunogenic and that the vaccine can be given subcutaneously in those patients where intramuscular administration is contra‐indicated.
ISSN:0931-0509
1460-2385
1460-2385
DOI:10.1093/ndt/17.10.1825